30483048|t|MicroRNA-210-5p Contributes to Cognitive Impairment in Early Vascular Dementia Rat Model Through Targeting Snap25.
30483048|a|Vascular dementia (VD) is the most common form of dementia in elderly people. However, little is understood about the role of microRNAs (miRNAs) involved in cognitive impairment in early VD. Here, a VD model induced by chronic cerebral ischemia and fetal bovine serum (FBS)-free cell model that detects synapse formation was established to investigate the function of miRNAs in early VD. The microarray analysis and real-time reverse transcription polymerase chain reaction (RT-PCR) showed that miR-210-5p increased significantly in the hippocampus of rats with 4 weeks of ischemia. The VD model rats also displayed significant cognitive deficits and synaptic loss. The overexpression of miR-210-5p decreased the synaptic number in primary hippocampal neurons, whereas specific suppression of miR-210-5p resulted in the formation of more synapses. Additionally, intracerebroventricular (ICV) injection of miR-210-5p agomir to VD rats aggravated phenotypes of cognitive impairment and synaptic loss. These VD-induced phenotypes were effectively attenuated by miR-210-5p antagomir. Moreover, bioinformatic prediction revealed that synaptosomal-associated protein of 25 KDa (Snap25) mRNA is targeted by miR-210-5p. The miR-210-5p decreased the luciferase activities of 3' untranslated region (3'UTR) of Snap25 mRNA. Mutation of predicted miR-210-5p binding sites in the 3' UTR of Snap25 mRNA abolished the miR-210-5p-induced decrease in luciferase activity. Western blot and immunofluorescence staining confirmed that miR-210-5p targets Snap25. Finally, RT-quantitative PCR (qPCR) and immunofluorescence staining detected that miR-210-5p agomir downregulated Snap25 expression in the cornu ammonis1 (CA1) region of hippocampi in VD rats, whereas miR-210-5p antagomir upregulated Snap25 expression. Altogether, miR-210-5p contributes to cognitive impairment in chronic ischemia-induced VD model through the regulation of Snap25 expression, which potentially provides an opportunity to develop a new therapeutic strategy for VD.
30483048	31	51	Cognitive Impairment	Disease	MESH:D003072
30483048	61	78	Vascular Dementia	Disease	MESH:D015140
30483048	79	82	Rat	Species	10116
30483048	107	113	Snap25	Gene	25012
30483048	115	132	Vascular dementia	Disease	MESH:D015140
30483048	134	136	VD	Disease	MESH:D015140
30483048	165	173	dementia	Disease	MESH:D003704
30483048	272	292	cognitive impairment	Disease	MESH:D003072
30483048	302	304	VD	Disease	MESH:D015140
30483048	314	316	VD	Disease	MESH:D015140
30483048	342	359	cerebral ischemia	Disease	MESH:D002545
30483048	499	501	VD	Disease	MESH:D015140
30483048	667	671	rats	Species	10116
30483048	688	696	ischemia	Disease	MESH:D007511
30483048	702	704	VD	Disease	MESH:D015140
30483048	711	715	rats	Species	10116
30483048	743	761	cognitive deficits	Disease	MESH:D003072
30483048	766	779	synaptic loss	Disease	MESH:D012183
30483048	1031	1037	agomir	Chemical	-
30483048	1041	1043	VD	Disease	MESH:D015140
30483048	1044	1048	rats	Species	10116
30483048	1074	1094	cognitive impairment	Disease	MESH:D003072
30483048	1099	1112	synaptic loss	Disease	MESH:D012183
30483048	1120	1122	VD	Disease	MESH:D015140
30483048	1244	1285	synaptosomal-associated protein of 25 KDa	Gene	25012
30483048	1287	1293	Snap25	Gene	25012
30483048	1323	1325	5p	Chromosome	5
30483048	1415	1421	Snap25	Gene	25012
30483048	1492	1498	Snap25	Gene	25012
30483048	1649	1655	Snap25	Gene	25012
30483048	1750	1756	agomir	Chemical	-
30483048	1771	1777	Snap25	Gene	25012
30483048	1841	1843	VD	Disease	MESH:D015140
30483048	1844	1848	rats	Species	10116
30483048	1891	1897	Snap25	Gene	25012
30483048	1948	1968	cognitive impairment	Disease	MESH:D003072
30483048	1980	1988	ischemia	Disease	MESH:D007511
30483048	1997	1999	VD	Disease	MESH:D015140
30483048	2032	2038	Snap25	Gene	25012
30483048	2135	2137	VD	Disease	MESH:D015140
30483048	Association	MESH:D003072	25012

